Hetero Drugs
A privately held Hyderabad generics group, the world's largest maker of HIV antiretrovirals, which launched Indian biosimilars of rituximab in 2015 and bevacizumab in 2016.
Overview
Hetero Drugs was founded in 1993 by B. Parthasaradhi Reddy, formerly chief technologist at Dr. Reddy's, and operates in more than 145 countries with over 30,000 employees. Best known as the largest producer of antiretroviral drugs and for low-cost hepatitis C generics, it has built a biosimilars portfolio for India that includes rituximab (2015, for non-Hodgkin lymphoma and chronic lymphocytic leukaemia), darbepoetin alfa (2015) and bevacizumab (2016, for metastatic colorectal cancer), and it supplies oncology active ingredients and generics globally.
Scorecard
All companies- approved products +12
- targets +4
- modalities +2
- regions +7
- registry trials +30
Rituximab was the first antibody ever approved for cancer (1997). It made chemoimmunotherapy the CLL standard for a decade, and biosimilars keep it cheap and everywhere.
The first drug to starve tumours of blood vessels. Approved in 2004 for bowel cancer, it remains a standard partner for chemotherapy in many cancers and is the add-on that makes late-line pills work better.
Pages like this
not linked directly; found by shared links- CompanyDr. Reddy's Laboratories
Shares Biosimilar, Rituximab, CD20, Monoclonal antibodies.
- IdeaMake the biosimilar the default at the pharmacy for trastuzumab, bevacizumab and rituximab
Shares Biosimilar, Rituximab, Bevacizumab, Prices and value.
- CompanyBiocon Biologics
Shares Biosimilar, Bevacizumab, VEGF / VEGFR, Monoclonal antibodies.
- CompanyBiocon
Shares Biosimilar, Bevacizumab, Monoclonal antibodies, Prices and value.
- CompanyIntas Pharmaceuticals (Accord Healthcare)
Shares Biosimilar, Prices and value.
- ProductOfatumumab
Shares Rituximab, CD20, Monoclonal antibodies.
- ProductIbritumomab tiuxetan
Shares Rituximab, CD20, Monoclonal antibodies.
- IdeaWHO prequalification plus pooled demand to push biosimilar prices below 10% of the originator
Shares Monoclonal antibodies, Prices and value, Most of the world has almost no cancer care.